In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al

Arthritis Rheum. 2005 Dec;52(12):4050-1; author reply 4051-2. doi: 10.1002/art.21610.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / administration & dosage*
  • Antirheumatic Agents / administration & dosage*
  • Cyclophosphamide / administration & dosage*
  • Drug Therapy, Combination
  • Humans
  • Lupus Nephritis / drug therapy*
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Antirheumatic Agents
  • Rituximab
  • Cyclophosphamide